ArticleACS medicinal chemistry letters2022
Indole-Containing Pyrazino[2,1-
Article in ACS medicinal chemistry letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- Anti-Inflammatory Evaluation of Pyrazino[2,1-Pharmaceuticals (Basel, Switzerland) · 2026Article
- Article
- Recent advances in quinazolinone derivatives: structure, design and therapeutic potential.Future medicinal chemistry · 2025Review
- Synthesis of Tricyclic and Tetracyclic Lactone Derivatives of Thieno[2,3-Molecules (Basel, Switzerland) · 2025Article
- Five New Indole Alkaloid Derivatives from Deep-Sea FungusMarine drugs · 2024Article
- Synthesis and Evaluation of Marine-Inspired Compounds Result in Hybrids with Antitrypanosomal and Antileishmanial Activities.Marine drugs · 2023Article
- Effect of Indole-Containing Pyrazino[2,1-Antibiotics (Basel, Switzerland) · 2023Article
- Review
- Fiscalin Derivatives as Potential Neuroprotective Agents.Pharmaceutics · 2022Article
- Medicinal Chemistry in Portugal and Spain: A Strong Iberian Alliance.ACS medicinal chemistry letters · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malaria, leishmaniasis, and sleeping sickness are potentially fatal diseases that represent a real health risk for more than 3,5 billion people. New antiparasitic compounds are urgent leading to a constant search for novel scaffolds. Herein, pyrazino[2,1-
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.